BRIEF—Two ADC firms deepen collab in oncology

Antibody-drug conjugate (ADC) specialists Adcendo and Duality Biologics have expanded an existing collaboration to develop ADCs, just a few months after they started working together.

In the original deal, Copenhagen’s Adcendo licensed China-based Duality’s linker-payload platform for its lead program in mesenchymal cancers.

The company has now negotiated terms to nominate additional ADCs against two novel targets.

Adcendo chief executive Michael Pehl said Duality’s platform was “becoming a cornerstone as we further build on our novel pipeline and continue on our way to becoming a leader in the field of ADC cancer therapy.”